Overview

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Status:
Recruiting

Trial end date:
2029-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Loxo Oncology, Inc.

Treatments:

Carboplatin
Pembrolizumab
Pemetrexed